Safety and Efficacy Study of GEB-101 Injection in Subjects With TGFBI-related Corneal Dystrophy

Open to people ages 18-70

• Males or females, age 18-70 years (inclusive).
• TGFBI gene mutation confirmed.
• Patients with corneal dystrophy who are symptomatic.
• Willing and able to give signed informed consent and follow study instructions.

• In either eye: Have any active infection, glaucoma, corneal disease, or other ocular conditions that may affect the assessment of efficacy or safety.
• In the study eye: Have a history of specific intraocular or corneal surgery, or the presence of active intraocular inflammation or vitreous hemorrhage.
• Patient with other corneal disorders that may hinder therapeutic surgery or interfere with the interpretation of study results.
• Prior gene therapy administration in either eye.
• Active infection occurring or suspected within 4 weeks prior to the investigational product, requiring systemic anti-infective therapy.
• Subjects with a history of major cardiovascular events within 6 months, the presence of any clinically significant condition, a diagnosis of malignancy within 5 years (with specified exceptions), or active infection with HIV, syphilis, hepatitis C, or hepatitis B.
• Female subjects who are pregnant, breastfeeding, or planning to become pregnant during the study period.
• Disease, condition, or disorder that in the judgement of Investigator could confound study assessments or limit compliance to study protocol.